[1] 中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识 [J]. 中华肾脏病杂志, 2020, (10): 781-792.
[2] Clase C M, Carrero J J, Ellison D H, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference [J]. Kidney Int, 2020, 97(1): 42-61.
[3] DuBose T D, Jr. Regulation of Potassium Homeostasis in CKD [J]. Adv Chronic Kidney Dis, 2017, 24(5): 305-314.
[4] Bansal S, Pergola P E. Current Management of Hyperkalemia in Patients on Dialysis [J]. Kidney Int Rep, 2020, 5(6): 779-789.
[5] Yusuf A A, Hu Y, Singh B, et al. Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study [J]. Am J Nephrol, 2016, 44(3): 179-186.
[6] Rossignol P, Lamiral Z, Frimat L, et al. Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey [J]. Nephrol Dial Transplant, 2017, 32(12): 2112-2118.
[7] Agiro A, Duling I, Eudicone J, et al. The prevalence of predialysis hyperkalemia and associated characteristics among hemodialysis patients: The RE-UTILIZE study [J]. Hemodial Int, 2022, 26(3): 397-407.
[8] Tsiagka D, Georgianos P I, Pikilidou M I, et al. Prevalence, recurrence and seasonal variation of hyperkalemia among patients on hemodialysis [J]. Int Urol Nephrol, 2022, 54(9): 2327-2334.
[9] Foley R N, Gilbertson D T, Murray T, et al. Long interdialytic interval and mortality among patients receiving hemodialysis [J]. N Engl J Med, 2011, 365(12): 1099-1107.
[10] Wouda R D, Vogt L, Hoorn E J. Personalizing potassium management in patients on haemodialysis [J]. Nephrol Dial Transplant, 2021, 36(1): 13-18.
[11] Rhee C M. Serum Potassium and the Long Interdialytic Interval: Minding?the?Gap [J]. Am J Kidney Dis, 2017, 70(1): 4-7.
[12] 黄耀禹, 王静, 王宁宁等. 维持性血液透析患者高钾血症及其反复发作的相关因素 [J]. 中华医学杂志, 2021, (42): 3484-3489.
[13] Nilsson E, Gasparini A, ?rnl?v J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system [J]. Int J Cardiol, 2017, 245: 277-284.
[14] Ni Z, Jin H, Lu R, et al. Hyperkalaemia prevalence and dialysis patterns in Chinese patients on haemodialysis: an interim analysis of a prospective cohort study (PRECEDE-K) [J]. BMC Nephrol, 2023, 24(1): 233.
[15] Kim Y, Yun S H, Koo H, et al. Different Seasonal Variations of Potassium in Hemodialysis Patients with High Longitudinal Potassium Levels: A Multicenter Cohort Study Using DialysisNet [J]. Yonsei Med J, 2021, 62(4): 315-324.
[16] Cheung A K, Yan G, Greene T, et al. Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients [J]. J Am Soc Nephrol, 2002, 13(9): 2345-2352.
[17] Usvyat L A, Carter M, Thijssen S, et al. Seasonal variations in mortality, clinical, and laboratory parameters in hemodialysis patients: a 5-year cohort study [J]. Clin J Am Soc Nephrol, 2012, 7(1): 108-115.
[18] Yamaguchi K, Kitamura M, Otsuka E, et al. Association between annual variability of potassium levels and prognosis in patients undergoing hemodialysis [J]. Clin Exp Nephrol, 2023, 27(10): 873-881.
[19] Kim T, Rhee C M, Streja E, et al. Racial and Ethnic Differences in Mortality Associated with Serum Potassium in a Large Hemodialysis Cohort [J]. Am J Nephrol, 2017, 45(6): 509-521.
[20] Casagrande S S, Wang Y, Anderson C, et al. Have Americans increased their fruit and vegetable intake? The trends between 1988 and 2002 [J]. Am J Prev Med, 2007, 32(4): 257-263.
[21] Picard K, Griffiths M, Mager D R, et al. Handouts for Low-Potassium Diets Disproportionately Restrict Fruits and Vegetables [J]. J Ren Nutr, 2021, 31(2): 210-214.
[22] Suh A, DeJesus E, Rosner K, et al. Racial differences in potassium disposal [J]. Kidney Int, 2004, 66(3): 1076-1081.
[23] Luft F C, Grim C E, Fineberg N, et al. Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages [J]. Circulation, 1979, 59(4): 643-650.
[24] 黄娜娅, 刘苑莹, 余健文等. 中国透析患者高钾血症现状分析 [J]. 中华医学杂志, 2021, (42): 3466-3471.
[25] Valdivielso J M, Carriazo S, Martin M, et al. Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men [J]. Clin Kidney J, 2024, 17(1): sfad212.
[26] Hasan M, Sutradhar I, Gupta R D, et al. Prevalence of chronic kidney disease in South Asia: a systematic review [J]. BMC Nephrol, 2018, 19(1): 291.
[27] Yang C, Yang Z, Wang J, et al. Estimation of Prevalence of Kidney Disease Treated With Dialysis in China: A Study of Insurance Claims Data [J]. Am J Kidney Dis, 2021, 77(6): 889-897.e881.
[28] 刘香红. 高通量血液透析对终末期肾病患者微炎性状态及细胞免疫的影响分析 [J]. 中国医学工程, 2021, 29(12): 93-96.
[29] Pun P H, Middleton J P. Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk [J]. J Am Soc Nephrol, 2017, 28(12): 3441-3451.
[30] Brunelli S M, Spiegel D M, Du Mond C, et al. Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients [J]. Nephrol Dial Transplant, 2018, 33(7): 1207-1214.
[31] Erratum Regarding "KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update" (Am J Kidney Dis. 2020;76[3][suppl 1]:S1-S107) [J]. Am J Kidney Dis, 2021, 77(2): 308.
[32] Gritter M, Vogt L, Yeung S M H, et al. Rationale and Design of a Randomized Placebo-Controlled Clinical Trial Assessing the Renoprotective Effects of Potassium Supplementation in Chronic Kidney Disease [J]. Nephron, 2018, 140(1): 48-57.
[33] Bernier-Jean A, Wong G, Saglimbene V, et al. Dietary Potassium Intake and All-Cause Mortality in Adults Treated with Hemodialysis [J]. Clin J Am Soc Nephrol, 2021, 16(12): 1851-1861.
[34] Ramos C I, González-Ortiz A, Espinosa-Cuevas A, et al. Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? [J]. Nephrol Dial Transplant, 2021, 36(11): 2049-2057.
[35] González-Ortiz A, Xu H, Ramos-Acevedo S, et al. Nutritional status, hyperkalaemia and attainment of energy/protein intake targets in haemodialysis patients following plant-based diets: a longitudinal cohort study [J]. Nephrol Dial Transplant, 2021, 36(4): 681-688.
[36] Garagarza C, Valente A, Caetano C, et al. Potassium Intake-(Un)Expected Non-Predictor of Higher Serum Potassium Levels in Hemodialysis DASH Diet Consumers [J]. Nutrients, 2022, 14(10).
[37] Narasaki Y, Okuda Y, Kalantar S S, et al. Dietary Potassium Intake and Mortality in a Prospective Hemodialysis Cohort [J]. J Ren Nutr, 2021, 31(4): 411-420.
[38] Saglimbene V M, Wong G, Ruospo M, et al. Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis [J]. Clin J Am Soc Nephrol, 2019, 14(2): 250-260.
[39] Kanda E, Morita N, Yajima T. Impact of chronic potassium binder treatment on the clinical outcomes in patients with hyperkalemia: Results of a nationwide hospital-based cohort study [J]. Front Physiol, 2023, 14: 1156289.
[40] Dépret F, Peacock W F, Liu K D, et al. Management of hyperkalemia in the acutely ill patient [J]. Ann Intensive Care, 2019, 9(1): 32.
[41] Lepage L, Dufour A C, Doiron J, et al. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD [J]. Clin J Am Soc Nephrol, 2015, 10(12): 2136-2142.
[42] Jaques D A, Stucker F, Ernandez T, et al. Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial [J]. Clin Kidney J, 2022, 15(10): 1908-1914.
[43] Noel J A, Bota S E, Petrcich W, et al. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age [J]. JAMA Intern Med, 2019, 179(8): 1025-1033.
[44] Laureati P, Xu Y, Trevisan M, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study [J]. Nephrol Dial Transplant, 2020, 35(9): 1518-1526.
[45] Zannad F, Hsu B G, Maeda Y, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study [J]. ESC Heart Fail, 2020, 7(1): 54-64.
[46] Packham D K, Rasmussen H S, Lavin P T, et al. Sodium zirconium cyclosilicate in hyperkalemia [J]. N Engl J Med, 2015, 372(3): 222-231.
[47] Dong L, Xu W, Deng Y, et al. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia [J]. Eur J Pharmacol, 2022, 931: 175174.
[48] Fishbane S, Ford M, Fukagawa M, et al. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE [J]. BMC Nephrol, 2022, 23(1): 59.
[49] Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia [J]. J Am Soc Nephrol, 2019, 30(9): 1723-1733.
[50] Spinowitz B S, Fishbane S, Pergola P E, et al. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study [J]. Clin J Am Soc Nephrol, 2019, 14(6): 798-809.
[51] Kovesdy C P, Rowan C G, Conrad A, et al. Real-World Evaluation of Patiromer for?the?Treatment of Hyperkalemia in?Hemodialysis Patients [J]. Kidney Int Rep, 2019, 4(2): 301-309.
[52] Amdur R L, Paul R, Barrows E D, et al. The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis [J]. Kidney Int, 2020, 98(5): 1331-1340.
[53] Di Palo K E, Sinnett M J, Goriacko P. Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting [J]. JAMA Netw Open, 2022, 5(1): e2145236.
[54] Butler J, Anker S D, Lund L H, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial [J]. Eur Heart J, 2022, 43(41): 4362-4373.
[55] Ganesan C, Pao A C. Spironolactone plus patiromer: proceed with caution [J]. Lancet, 2019, 394(10208): 1486-1488.
